argenx SE (ARGX)

Industry Biotechnology


This stock can be held in an Investment ISA and an Investment Account
Sell

€669.60

Buy

€669.80

arrow-down€-1.40 (-0.21%)

Prices updated at 08 May 2026, 16:08 CEST
| Prices minimum 15 mins delay
|
Prices in EUR

argenx SE, along with its subsidiaries is engaged in the bio-technical research on drugs and pharma processes for the treatment of oncological, autoimmune and inflammatory diseases.
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Peter K.M. Verhaeghe
CEO
Mr. Tim Van Hauwermeiren, M. Sc.
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
1,863
Head office
Laarderhoogtweg 25
Amsterdam
Netherlands
1101EB
mobile
+31 107038441
letter
info@argenx.com

Key personnel

Salary
Mr. James M. Daly
Independent Director
0.10m
Mr. Steven E. Krognes, M.B.A.
Independent Director
0.10m
Mr. Tim Van Hauwermeiren, M. Sc.
Executive Director and Chief Executive Officer
0.83m
Mr. Peter K.M. Verhaeghe
Non-Executive Chairman of the Board
0.14m
Dr. Pamela M. Klein, M.D.
Independent Director
0.08m
Mr. Anthony A. Rosenberg
Independent Director
0.08m
Dr. Brian L. Kotzin, M.D.
Independent Director
0.09m
Ms. Camilla Sylvest
Independent Director
0.07m
Mr. Arjen Lemmen
Vice President, Corporate Development and Strategy
-
Ms. Andria Wilk
Global Head, Quality
-
Mr. Karl Gubitz
Chief Financial Officer
0.58m
Ms. Malini Moorthy
General Counsel and Corporate Secretary
-
Dr. Luc Truyen, M.D.,PhD
Chief Medical Officer
-
Dr. Ana Cespedes, PhD
Independent Director
0.08m
Dr. Peter Ulrichts
Chief Scientific Officer
-
Ms. Karen Massey
Chief Operating Officer
0.74m

Top 5 shareholders

No. of shares
Vanguard2,178,901
Wellington Management Company LLP1,345,077
BlackRock Fund Advisors1,216,002
Vanguard Health Care Fund1,146,086
Principal Global Investors LLC1,053,554

Director dealings

Action
No data
Please note that past performance is not a reliable indicator of future returns.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2026 Morningstar. All rights reserved.